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Background aims. Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic
approaches. However, a characterization of the population of adipose-derived stromal and stem cells (ASCs) with the
greatest therapeutic potential remains unclear. Under the authority of International Federation of Adipose Therapeutics and
International Society for Cellular Therapy, this paper sets out to establish minimal deﬁnitions of stromal cells both as
uncultured stromal vascular fraction (SVF) and as an adherent stromal/stem cells population. Methods. Phenotypic and
functional criteria for the identiﬁcation of adipose-derived cells were drawn from the literature. Results. In the SVF, cells are
identiﬁed phenotypically by the following markers: CD45-CD235a-CD31-CD34þ. Added value may be provided by both
a viability marker and the following surface antigens: CD13, CD73, CD90 and CD105. The ﬁbroblastoid colony-forming
unit assay permits the evaluation of progenitor frequency in the SVF population. In culture, ASCs retain markers in common
with other mesenchymal stromal/stem cells (MSCs), including CD90, CD73, CD105, and CD44 and remain negative for
CD45 and CD31. They can be distinguished from bone-marrow-derived MSCs by their positivity for CD36 and negativity
for CD106. The CFU-F assay is recommended to calculate population doublings capacity of ASCs. The adipocytic,
chondroblastic and osteoblastic differentiation assays serve to complete the cell identiﬁcation and potency assessment in
conjunction with a quantitative evaluation of the differentiation either biochemically or by reverse transcription polymerase
chain reaction. Conclusions. The goal of this paper is to provide initial guidance for the scientiﬁc community working with
adipose-derived cells and to facilitate development of international standards based on reproducible parameters.
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642 P. Bourin et al.community about the identity of adipose tissue-derived
cell populations.This ﬁeld is at a juncture similar to that
faced a few years ago by the ﬁeld of bone marrow
mesenchymal stromal/stem cells (MSCs). Under the
authority of the International Society for Cellular
Therapy (ISCT), researchers in the MSC ﬁeld issued
a bold statement deﬁning the identity of the MSC (1).
Our intent in this paper is to build such a statement
under the joint authorities of the International Federa-
tion of Adipose Therapeutics and Sciences (IFATS)
and the ISCT describing both stromal cells from the
stromal vascular fraction (SVF) of the adipose tissue
and the adipose tissue-derived stromal cells. Recog-
nizing that this is a dynamicﬁeld thatwill require further
standardization, our goal is to establish a “living”
document that will bemodiﬁed in response to new data
and ﬁndings from ongoing and future pre-clinical and
clinical studies. This document does not intend to
establish policies that may restrict future advances;
rather, it is designed to provide guidance that promotes
further biologic clariﬁcations, best clinical practices and
safety to improve efﬁcacious adipose tissue-derived cell
therapies that beneﬁt society.Deﬁnitions
The following deﬁnitions are pertinent to our discus-
sion. Stromal cells are connective tissue cells of any
organ. A progenitor is cell that has a limited prolifer-
ation potential and is able to differentiate into one or
several speciﬁc cell types. A stem cell is here charac-
terized by its ability to self-renew and its multipotency.
Status of adipose tissue for cell engineering and
regenerative medicine
The medical community and general public percep-
tion of adipose tissue as an organ has changed
dramatically over the past 4 decades. Within this
period, the incidence of obesity has increased
substantially, reaching levels of 30% of the pop-
ulation of many economically advantaged nations.
Although obesity is less common in economically
developing countries, numbers of overweight and
obese citizens in these countries also have increased.
Increased obesity has led to changes in medical
practices, one of which is far greater numbers of
elective surgical abdominoplasties and lipoaspirates.
Although adipose tissue has been routinely discarded
as a medical waste, plastic surgeons and other in-
vestigators have documented the use of adipose tissue
as an abundant and accessible source of multipotent
stromal cells for regenerative medicine (2). Since
initial reports in the late 1960s (3), multiple inde-
pendent laboratories have established that stromal
cells similar to those identiﬁed in bone marrow (4)can be isolated in a reproducible manner from adipose
tissue that is either resected as intact tissue or aspi-
rated using tumescent liposuction (5,6). Although
a common procedure is lacking, in general minced
adipose tissue is digested by one or more of the
following: collagenase, dispase, trypsin or related
enzymes. A consensus exists regarding temperature
(37C), digestion duration times (range, 30 min to>1
h) and ratios of tissue weight to volume; however,
protease concentrations are far more variable.
Following the neutralization of the enzymes, the
released elements, deﬁned as the SVF, are separated
from the mature adipocytes by differential centrifu-
gation, which can substantially differ according to the
protocols. The SVF consists of a heterogeneous
mesenchymal population of cells that includes not
only adipose stromal and hematopoietic stem and
progenitor cells but also endothelial cells, erythro-
cytes, ﬁbroblasts, lymphocytes, monocyte/macro-
phages and pericytes, among others (7e11). When
SVF cells are seeded into culture, a subset of elon-
gated cells begins to adhere to the tissue culture
plasticware. These cells can be puriﬁed further using
a combination of washing steps and culture expansion
with media similar to the ones used for bone marrow
MSCs to deplete most of the hematopoietic cell
population from the SVF cells. This process allows
the emergence of an adherent cell population termed
adipose tissue-derived stromal cells (ASCs). Although
ASCs are less heterogeneous than SVF cells, they are
by no means homogeneous. ASCs include multi-
potent cells with the ability to differentiate into
adipocytes, chondrocytes, and osteoblasts, among
other lineage pathways (2,12e16). In this respect, the
ASCs exhibit properties similar to bone marrow
MSCs, leading some investigators to suggest that the
two populations are identical; however, numerous
features distinguish these two cell populations. For
example, ASCs seem more prone to differentiate into
muscle cells or even into cardiomyocytes compared
with bone marrowMSCs (17), while being less robust
in chondrogenic and osteogenic properties according
to some reports (18,19). Variability between the ASCs
and bone marrow MSCs may reﬂect, in part, the
different microenvironment or “niches” where these
cells reside in their respective tissues of origin and the
differences in ex vivo expansion protocols.
Clinical research on these adult stromal cell
populations has accelerated, and multiple clinical
investigations are underway to examine the use of
ASCs, SVF cells, and bone marrow MSCs for tissue
engineering and regenerative medical applications
(20e22). Methods to isolate SVF cells using
mechanical, non-enzymatic techniques are being
developed, and some have been applied in clinical
practice. For these reasons, it is time to develop a
Table II. Cell populations resident in SVF.
Hematopoietic-lineage cells
Stem and progenitor cells <0.1%
Granulocytes 10e15%
Monocytes 5e15%
Lymphocytes 10e15%
Endothelial cells 10e20%
Pericytes 3e5%
Stromal cells 15e30%
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and properties of human stromal cells from SVF cells
and ASCs. We have restricted our description of the
heterogeneous SVF cell populations to stromal cells
alone because ASCs are derived from this SVF sub-
population. Such information will begin to establish
a common deﬁnition and terminology that will
facilitate communication across the academic,
biotechnology, medical and regulatory communities,
ensuring that patients will beneﬁt from safe and
efﬁcacious adipose tissue-derived cell products in the
near future. In the following sections, we present
recommended parameters for a basic characteriza-
tion of both SVF cells and ASCs.Phenotyping SVF
Compared with the bone marrow mononucleated
fraction generating MSCs, the SVF contains a higher
percentage of stromal elements (Table I), although
multiple other lineages, most notably those of endo-
thelial, hematopoietic and pericytic origin, are also
present (11e13,23). Endothelial, hematopoietic and
pericytic lineages represent 10e20%, 25e45% and
3e5%, respectively, of the total nucleated cells
(Table II). The degree of heterogeneity depends, in
part, on the adipose tissue depot site and the digestion
protocol; there are no sufﬁcient data on the impact of
these different enzymatic and mechanical procedures
in antigen expression. Because there is no single
marker to identify SVF cell sub-populations and the
ones used are not exclusive of a mononucleated sub-
population, we suggest using multi-color identiﬁca-
tion with a combination of ﬂuorochrome-labeled
antibodies to surface antigens and one viability
marker. The latter is recommended to eliminate dead
or apoptotic cells induced by the isolation protocol,
which could distort the analysis. Viability is recom-
mended to be >70% to allow for good cell expansion.
Careful attention should be given in obtaining single
cell suspensions before the analyses to avoid cellTable I. Differences between bone marrow and adipose tissue.
SVF BM-NC ASC MSC
CD34 þ   
CD45 þ þþ  
CD13  þþ þþ þþ
CD73   þþ þþ
CD90   þþ þþ
CD105   þþ þþ
CD10 þþ 
CD36 þ 
CD106  þ
CFU-F >1% >0.001% >5% >5%
þþ ¼ >70%, þ ¼ >30e70%,  ¼ >2e30%,  ¼ <2%.
BM-NC, bone marrow nucleated cells.doublets and overlapping phenotypes in ﬂuorescence-
activated cell sorter assessment as a result of cell
clustering. The analysis additionally should rely
on well-standardized gating parameters as critical
aspects, given the presence of debris from the diges-
tion and possible non-speciﬁc binding (Figure 1).
For the stromal component of the SVF, based on
existing literature, we propose a combination of
negative and positive markers. CD45 (leukocyte
common antigen) is the classic marker to identify cells
of hematopoietic origin except for red blood cells and
should be excluded. As an alternative to erythrocyte
lysis (a standard method to remove erythrocytes), we
propose the inclusion of CD235a (glycophorin A) to
monitor directly any contaminating erythroid lineage
cells. Despite the fact that many SVF isolation proto-
cols include a means to eliminate red blood cells (i.e.,
ammonium chloride or density gradients), it remains
to be determined whether this process could disturb
the ﬁnal analysis. CD31 (PECAM-1) is a classic
marker for endothelial cells and their progenitors,
although it is also detected on platelets and leukocytes.
In combination with CD45, CD31 allows the exclu-
sion of CD45CD31þ endothelial populations. CD34
expression is shared by hematopoietic stem/progenitor
cells and endothelial cells (8,24e26). However,
according to published data from our groups and
others, it is also a potential marker that should be used
to identify the stromal cell-containing population
(8,24e26). There are multiple classes of CD34 anti-
bodies recognizing unique immunogens. Conse-
quently, the choice ofCD34antibody can substantially
inﬂuence the signal intensity detected on a given cell
population. Based on the current literature (27), we
recommend the use of class III CD34 antibodies for
SVF cell characterization (i.e., clone 581 or 4H11).
Within the SVF, some studies have characterized
a stromal cell population, excluding hematopoietic
and endothelial cells, based on the following combi-
nation: CD45CD235aCD31CD34þ. According
to different publications, this population represents at
least 20% of the cells of the SVF (15). The percentage
of CD34þ cells depends on the method of adipose
tissue harvest, the degree of vascular hemorrhage and
the subsequent digestion and isolation techniques.
Four additional markers have been used to identify
Figure 1. Illustration of a strategy for the analysis of the cells of the SVF by ﬂow cytometry. The cell suspension undergoes a red blood cell lysis
before antibody labeling, and dead cells are excluded by DAPI labeling. (A) Analysis of live (Dapi) and dead (Dapiþ) cells. (B) Forward and
side scatterplot gated on live cells to identify the cell populations; the gate excludes the cell debris. (C) The markers CD34 and CD45
distinguish two different CD34þ cell populations according to CD45. Stromal cells are CD34brightCD45. (D) The marker combination CD34
and CD31 distinguishes stromal cells CD34brightCD31 from the endothelial cells CD34þCD31þ. (E, F) An example of analysis of CD45 cell
populations using CD34 and CD73 or CD90 markers. Most of the CD45CD34bright cells are CD73þ or CD90þ. The antibodies were
purchased from Becton-Dickinson (San Jose, CA, USA), Beckman-Coulter (Miami, FL, USA), eBioscience (San Diego, CA, USA) and
Biolegend (San Diego, CA, USA). The plots came from several laboratories of the authors.
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(Thy-1) and CD105 (Endoglin). Because CD90 and
CD105 are also expressed by the endothelial pop-
ulation, they may not be optimal selections as sole
markers but are best used in combination with others.
Both CD13 and CD73 markers are highly expressedon theCD45CD31CD34þ cell population andmay
help to identify stromal cells better. CD13þ and
CD73þ cells have been described to represent around
80% and 70% of the CD45CD31CD34þ cell pop-
ulation, respectively (26). Alternative positive stromal
cell markers, including CD10 (CALLA), CD29
Adipose stromal cells: IFATS and ISCT statement 645(b1 integrin), and CD49 (VLA) isoforms, have been
identiﬁed, and these can also be considered for char-
acterization purposes.Fibroblastoid colony-forming unit evaluation
The ﬁbroblastoid colony-forming unit (CFU-F) assay
is the standard to deﬁne the number of progenitor
cells. This assay, modiﬁed from the one performed for
bonemarrowMSCs (28), takes 11e14 days of culture
(29). The cell suspension of SVF should be seeded at
low density (40e400 cells/cm2) to allow each clone to
grow separately in a medium carefully chosen to allow
clone growth (29). After ﬁxation and staining, clones
with >50 cells are enumerated. In general,
the frequency of stromal progenitors ranges from
1%e10% relative to the total nucleated cell pop-
ulation. It is recommended that the CFU-F assay be
performed at least with two or more cell concentra-
tions in triplicate for each donor to minimize assay
variations. The number of colonies allows for an
estimation of the rate of doubling of the population
during the primary phase of culture. The information
gained from CFU-F would be particularly useful toTable III. Guidelines for characterization of adipose tissue-derived cells
Feature Assay Cells o
Viability
Vital stain
by ﬂow cytometry
or microscopy >70%
Immunophenotype Flow cytometry Primary stable p
markers for str
CD13, CD29,
CD90 (>40%
Primary negative
stromal cells:C
CD45 (<50%
Proliferation and
frequency
CFU-F Anticipated frequ
Adipogenic
differentiation
Histochemistry,
RT-PCR, Western
blot immunoblot,
ELISA
Chondrogenic
differentiation
Osteogenic
differentiation
The information in this table represents recommended guidelines only
deﬁnitions at this time. The level of positivity for surface antigens may var
been noted for the markers CD34, CD49d and CD146.
C/EBPa, CCAAT enhancer binding protein a; ELISA, enzyme-linked im
peroxisome proliferator activated receptor g; RT-PCR, reverse transcripenhance the quality control of any resulting cell
therapy product.Identiﬁcation of ASCs after culture
We propose the following main features and optional
properties.Phenotyping ASCs
As described earlier, ASCs are selected by adhesion
from SVF cells and are related to MSCs, just as
SVF cells can be compared with the bone marrow
mononuclear cell fraction (Tables I,III). One main
difference between SVF cell and ASC suspensions
is the high level of CD45þ cells in the SVF cells and
the low or undetectable level in ASCs. We propose
to adapt the characterization strategy for MSCs as
presented in the ISCT statement paper with some
modiﬁcations as guidelines for the better charac-
terization of these adipose precursors (1). As
employed for the phenotyping of the SVF cells,
we suggest the use of multi-color analysis. Flow
cytometry can be used to deﬁne and validate the.
f SVF ASCs
viable >90% viable
ositive
omal cells:
CD44, CD73,
), CD34 (>20%)
markers for
D31 (<20%),
)
Primary stable positive markers: CD13,
CD29, CD44, CD73, CD90, CD105
(>80% in ASC)
Primary unstable positive marker: CD34
(present at variable levels)
Primary negative marker: CD31, CD45,
CD235a (<2%)
Secondary other positive markers: CD10,
CD26, CD36, CD49d, CD49e
Secondary other low or negative markers:
CD3, CD11b, CD49f, CD106,
PODXL
ency: >1% Anticipated frequency: >5%
Histology: oil red O, Nile red or stain
speciﬁc for lipid inclusions
Biomarkers: adiponectin, C/EBPa,
FABP4, leptin, PPARg
Histology: alcian blue or safranin O
Biomarkers: aggrecan, collagen type II,
Sox 9
Histology: alizarin red or von Kossa
Biomarkers: alkaline phosphatase, bone
sialoprotein, osteocalcin, osterix, runx2
and is not to be construed as industry standards or regulatory
y between ASCs and SVF cells because differences in intensity have
munosorbent assay; FABP4, fatty acid binding protein 4; PPARg,
tion polymerase chain reaction.
646 P. Bourin et al.relative homogeneity or, alternatively, the hetero-
geneity (i.e., potential contamination) of the ASCs.
A viability dye should be included, particularly
if a viability dye such as trypan blue is not included
when counting or if the frequency of dead cells
is >30%. The immunophenotype should be com-
parable to the immunophenotype used to deﬁne the
SVF cells, identifying a population enriched for
CD45CD31. We recommend that the analysis
include surface antigens used to characterize the
MSCs: CD73, and CD90 (Table III). In addition,
we suggest including CD13 as an alternative or
supplement to CD105 for two reasons: (i) the
commercial antibodies targeting this antigen
exhibit higher speciﬁcity and signal intensity, and
(ii) the expression level is often higher and more
stable. However, it remains possible that there will
be added value in distinguishing between the
properties of CD105 and CD105þ ASC sub-
populations.
ASCs should be negative (<2%) for hematopoietic
markers such as CD11b and CD45 and positive
(>90%) for stromal markers such as CD13, CD73 and
CD90 (Tables I,III). In addition, to distinguish ASCs
from marrow MSCs, we propose using two other
markers, CD36 (GPIIIb) and CD106 (VCAM-1),
because it has been published that ASCs, in contrast to
MSCs, do not express CD106 but are positive for
CD36 (24,26,30). As an example of comparison, we
provide a phenotypic analysis of MSCs and ASCs in
Figure 2. The expression of CD34 greatly depends on
the culture condition. It is generally expressed during
the early phase of culture (within 8e12 population
doublings after culture of the SVF), but then its
expression decreases with continued cell division as
reported earlier (9,26). We propose that a founda-
tional phenotyping should include at least two nega-
tive markers and two positive markers in the same
analysis. Additional markers will strengthen the
characterization. We suggest CD10, CD26 (DPPIV),
CD49d (VLA4), CD49e (VLA5) and CD146
(MUC18) as additional positive markers but with
variable expression depending on the donor or
culture passage and CD3, CD11b (Mac-1), CD49f
(VLA6) and Podocalyxin like protein (PODXL) as
markers with negligible expression (<2%) levels
(Table III). Even when deﬁned by these basic surface
antigens, we anticipate that ASC populations may
further display heterogeneity for additional surface
antigens (24).Functionality of ASCs
Ahallmark of theASCs is theirmultipotency and ability
give rise to osteoblastic, chondrocytic and adipocytic
lineages (2,5,12). Differentiation protocols have beenextensively published, and some manufacturers offer
“off-the-shelf” lineage-speciﬁc inductive media. Al-
though a qualitative assessment of the differentiation
based on histochemistry is helpful, it may not be
sufﬁcient for rigorous analysis. For instance, many
cells can store lipids with no expression of adipocyte
differentiation program (i.e., hepatocytes, muscle
cells). A quantitative approach may be beneﬁcial
for the characterization and documentation of ASC
differentiation potential. A selection of lineage-speciﬁc
gene or protein biomarkers can be made from the
following based on published data: for adipogenesis
(adiponectin, fatty acid binding protein 4, leptin,
peroxisome proliferator activated receptor g, glycerol
3 phosphate dehydrogenase); for chondrogenesis,
aggrecan, collagen type II, Sox9; for osteogenesis,
alkaline phosphatase, bone sialoprotein, osteocalcin,
osterix, runx2 (2,12,13,31,32).Within dedicated read-
outs for speciﬁc intent, onemay assess the cell function
by up-regulation of biomarkers. To adopt a coherent
approach with the characterization of the SVF, we also
suggest performing an evaluation of progenitor
frequency by a secondary CFU-F assay where passage
1 ASCs are seeded at a density of 2e4 cells/cm2 and
evaluated for colony formation after an 11e14 day
incubation period.Conclusions
The goal of this paper is to provide initial guidance to
academia, industry and regulatory authorities re-
garding the minimal properties expected for adipose
tissue-derived cells (summarized in Table III). The
features described in this paper are designed to facilitate
further progressive development of international stan-
dards based on reproducible parameters and endpoints
that will possibly harmonize cellular products across
boundaries and accelerate the delivery of safe and
effective ASC-based tools to the medical community
and the patients it serves. This characterization may be
completed in relation to speciﬁc uses of ASCs or SVF
cells. For example, it may be important to test the
secretion of a deﬁned factor or to evaluate a speciﬁc set
of genes,microRNAs or proteins expressed byASCs as
a quantiﬁable potency test. By establishing a deﬁned set
of quality control criteria that are accepted across
clinical disciplines and international boundaries, the
pace of discovery and proofs of efﬁcacy and safety will
accelerate for adipose tissue-derived cell products.
Additionally, it will be important to reﬁne and stan-
dardize assays and methods used to quantify adipose
tissue-derived cells in a reproducible manner. In
addition to developing shared standard operating
procedures for each assay, it may be useful to establish
international reference laboratories for individual tests.
These outcomes are likely to beneﬁt all constituencies,
Figure 2. A phenotypic comparison of cultured ASCs (left column) and MSCs (right column) showing similarities (CD73, CD90) and
differences (CD10, CD36 and CD106) between the two types of stromal cells. The plots came from several laboratories of the authors.
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nologists, who share a stake in the promising ﬁeld of
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